The Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Receiving Tocilizumab: A Systematic Review and Meta-Analysis.
Ping-Hung KoMeng Hsuan KuoI-Ting KaoChen-Yi WuChih-Wei TsengShih-Chieh ShaoPublished in: Viruses (2024)
cannot be ignored but may be avoided. Clinicians should consider implementing appropriate antiviral prophylaxis and monitoring policies for RA patients to avoid unnecessary hepatic side effects from tocilizumab treatment.
Keyphrases
- rheumatoid arthritis
- hepatitis b virus
- disease activity
- end stage renal disease
- chronic kidney disease
- public health
- ejection fraction
- ankylosing spondylitis
- interstitial lung disease
- newly diagnosed
- rheumatoid arthritis patients
- liver failure
- peritoneal dialysis
- prognostic factors
- systemic sclerosis
- quality improvement
- patient reported
- smoking cessation
- idiopathic pulmonary fibrosis